

Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel (CAORG) Prior Authorization Ordering Instructions

Mayo Clinic Laboratories is pleased to offer prior authorization services and third party billing on our Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel, Varies (CAORG). To utilize our prior authorization services on this test, you must follow the process as outlined below.

Ordering and Prior Authorization Process

Mayo Clinic Laboratories utilizes an extract and hold process for prior authorization. To order CAORG with prior authorization services, complete this document as instructed below by insurance type. You must order test code CAORG and send the completed paperwork in with the sample. The receipt of the paperwork and sample at Mayo Clinic Laboratories will trigger the extract and hold process and generate a request to the MCL Business Office to verify your patient's insurance coverage for the testing and begin any additional prior authorization services.

If the expected patient out-of-pocket expense is \$200 or less after prior authorization services, Mayo Clinic Laboratories will automatically proceed with CAORG testing. If the expected patient out-of-pocket expense is greater than \$200, Mayo Clinic Laboratories will seek approval from the client contact listed on the Patient Demographics and Third Party Billing Information form **before proceeding** with CAORG testing. The MCL Business Office offers interest-free payment plans on balances over \$200.

Commercial Insurance

For patients with commercial insurance, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Letter of Medical Necessity (required)
- · Copy of front and back of insurance card (if available)

Note: The Advanced Beneficiary Notice of Noncoverage (ABN) form is not required for commercial insurance-covered patients.

Medicare

For patients with Medicare, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Advanced Beneficiary Notice of Noncoverage (ABN) form (required see separate ABN form: MC2934-321)
- Copy of front and back of secondary insurance card (if applicable)

Attach the ABN form and copy of the secondary insurance card to the Patient Demographics and Third Party Billing Information form and send with the specimen.

Note: The Letter of Medical Necessity and a copy of the Medicare card are not required for Medicare-covered patients.

Medicaid

Mayo Clinic Laboratories may be able to file claims for your Medicaid-covered patients. Before ordering, contact the MCL Business Office at 800-447-6424 to discuss. Have the patient's Medicaid information available when calling.

Note: These instructions are subject to change at any time. Call the MCL Business Office at 800-447-6424 with any questions.



Prior Authorization Patient Demographics and Third Party Billing Information

Patient Demographics	and Insurance	Information			
Patient Name (Last, First Middle)			,	Birth Dat	e (mm-dd-yyyy)
0 4 1 1 1 1 1 1			1 1/61	: 0	
Sex Assigned at Birth ☐ Male ☐ Female ☐ Ur	nknown 🗆 Choo	se not to disclose	Legal/Adminis ☐ Male ☐ □		inany
Patient Mailing Address	IKHOWH 🗀 CHOO	se not to disclose	City	State	ZIP Code
Primary Insurance Company	Name	Insurance Subscribe	er ID No. / Policy No.	Insurance Group	No. (if applicable)
, ., , . , . , . , . , . ,					.,
Primary Insurance Company	Mailing Address	·	City	State	ZIP Code
Primary Insurance Company Phone Subscriber Name (if		f different than patient) and Relationship to Patient			
Order Information					
MCL Test ID	Name (of desired MCL test	1	l l	-
CAORG	Compr	ehensive Marfan, Loeys-D	ietz, Ehlers-Danlos, a	nd Aortopathy Ge	ne Panel, Varies
ICD-10 Codes (use number c	odes to highest spe	ecificity)		Service/Collection	on Date (mm-dd-yyyy)
Referring Provider Name (Last, First)		Referring Provider's National Provider ID (NPI)			
Client Account and Cli	ent Contact In	formation		-	
MCL Client Account Number		Referring Client Fac	ility Name		
			Contact Phon	e	
Contact Name			Oontact Hon		
			Date Today (m	m-dd-yyyy)	
Contact Name Contact Email	This Commission	od Forms		m-dd-yyyy)	
Contact Name Contact Email Attach the Following to			Date Today (m		
Contact Name Contact Email Attach the Following to Letter of Medical Necessity	y (required except f	or Medicare patients) – ter	Date Today (m	ge 3	rm: MC2934-321
Contact Name Contact Email Attach the Following to	y (required except f ce of Noncoverage	or Medicare patients) – ter (ABN) form (required for N	Date Today (m	ge 3	rm: MC2934-321

Page 2 of 4 MC7226-35rev1224

Letter of Medical Necessity for Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel (CAORG) Testing

Patient Name (Last, First Middle)
Birth Date (mm-dd-yyyy)
Member Number
Group
ICD-10 Codes
To Whom It May Concern:
We are requesting preauthorization for the Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel, Varies
(CAORG) performed by Mayo Clinic Laboratories for (insert patient name)
Patient's personal medical history is significant for
Patient's family history is significant for

Due to the patient's medical history, a diagnosis of Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, or other inherited aortopathy condition is suspected, and genetic testing is recommended.

Rationale: The use of genetic testing to aid in the diagnosis of Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, and other inherited aortopathies is supported by experts in the field.¹² Test results will have a direct impact on this patient's medical management, screening, and prevention of potential complications, including sudden death due to aortic dissection.

Genetic testing is used to confirm a diagnosis and/or identify at-risk individuals. This testing would detect a gene variant causative of the patient's medical history, and would have significant implications for the patient's clinical management regarding decision making and medical management. For example, a genetic diagnosis of Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, or other inherited aortopathy would warrant ongoing echocardiograms and cardiovascular imaging, and potentially prevent aortic aneurysm and/or dissection. Additionally, identification of a diagnostic genetic variant would guide management. For example, if a variant is identified in one of the genes associated with multiple aneurysms (*TGFBR1*, *TGFBR2*, *SMAD3*, *TGFB2*, or *ACTA2*), screening of the head and neck, and potentially other regions of the arterial tree, would be initiated to appropriately manage risk. Alternatively, identification of an *FBN1* variant would eliminate the need for this additional screening since aneurysms are typically isolated to the thoracic aorta in Marfan syndrome. Additionally, a variant associated with Loeys-Dietz syndrome would provide evidence that earlier surgical intervention on the aorta would be required, given that individuals with this condition are known to experience aortic dissection at smaller aortic dimensions. Finally, diagnosis of Ehlers-Danlos syndrome is gene based, and management and screening recommendations vary widely among the subtypes of this condition. In summary, a positive genetic test result would provide a definitive cause for this patient's medical history and would ensure this patient is being treated appropriately.

A negative genetic test result could also be informative. A negative result may help to reinforce that the patient does not have Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, or other inherited aortopathy condition. Alternatively, it could indicate that additional genetic testing (such as whole exome or whole genome sequencing) should be considered to confirm an alternate diagnosis and allow for gene-specific management and screening.

Genetic testing can confirm a diagnosis of Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome or other inherited aortopathy condition. Additionally, a positive result may mean family members are at up to a 50% risk of being affected with, or a carrier, for one of these conditions. When a familial variant has been identified, genetic testing can identify family members who are not at increased risk to develop one of these conditions. No other test can reliably differentiate unaffected family members, who do not require further health screening from presymptomatic affected family members who must be followed closely by a team of specialists.

Page 3 of 4 MC7226-35rev1224

Test requested: Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel, Varies (CAORG) is a cost-effective test that utilizes next-generation sequencing (NGS), to evaluate 48 genes for disease-associated variants associated with Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, and other inherited aortopathies.

Laboratory information: Testing would be performed at Mayo Clinic Laboratories (TIN# 411346366 / NPI# 1093792350), a CAP-accredited and CLIA-certified laboratory, using 2020 CPT code: 81410.

	Thanl	c vou for	vour thoughtfu	ul consideration of	our preauthorization red	guest. We look forwai	d to hearing back from y
--	-------	-----------	----------------	---------------------	--------------------------	-----------------------	--------------------------

Sincerely,

Ordering Provider Name	e
· ·	
Contact information	

References

- 1. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179
- 2. Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):e334-e482. doi:10.1161/CIR.000000000001106

Page 4 of 4 MC7226-35rev1224

MAYO CLINIC LABORATORIES

200 First Street SW Rochester, Minnesota 55905 800-447-6424

Patient Name (First Middle Last)	MCL Order Number	

Advance Beneficiary Notice of Noncoverage (ABN)

Note: If Medicare doesn't pay for Items and Services below, you may have to pay.

Medicare does not pay for everything, even some care that you or your health care provider have good reason to think you need. We expect Medicare may not pay for the Items and Services below.

Items and Services	Reason Medicare May Not Pay	Estimated Cost
CAORG / Comprehensive Marfan, Loeys-Dietz, Ehlers-Danlos, and Aortopathy Gene Panel, Varies	Patient's personal and family history of cancer does not meet Medicare's medical necessity coverage criteria for this laboratory test.	\$2,600.00

WHAT YOU NEED TO DO NOW:

- Read this notice, so you can make an informed decision about your care.
- Ask us any questions that you may have after you finish reading.
- Choose an option below about whether to receive the Items and Services listed above.

Note: If you choose Option 1 or 2, we may help you to use any other insurance that you might have, but Medicare cannot require us to do this.

Options: Check only one box. We cannot choose a box for you.			
OPTION 1.	I want the Items and Services listed above. You may ask to be paid now, but I also want Medicare billed for an official decision on payment, which is sent to me on a Medicare Summary Notice (MSN). I understand that if Medicare doesn't pay, I am responsible for payment, but I can appeal to Medicare by following the directions on the MSN. If Medicare does pay, you will refund any payments I made to you, less co-pays or deductibles.		
OPTION 2.	I want the Items and Services listed above, but do not bill Medicare. You may ask to be paid now as I am responsible for payment. I cannot appeal if Medicare is not billed.		
\square option 3.	I don't want the Items and Services listed above. I understand with this choice I am not responsible for payment, and I cannot appeal to see if Medicare would pay.		
Additional Info	rmation:		

This notice gives our opinion, not an official Medicare decision. If you have other questions on this notice or Medicare billing, call **1-800-MEDICARE** (1-800-633-4227/**TTY**: 1-877-486-2048).

Signing below means that you have received and understand this notice. You may ask to receive a copy.

Signature	Date (mm-dd-yyyy)

You have the right to get Medicare information in an accessible format, like large print, Braille, or audio. You also have the right to file a complaint if you feel you've been discriminated against. Visit Medicare.gov/about-us/accessibility-nondiscrimination-notice.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0566. The time required to complete this information collection is estimated to average 7 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Baltimore, Maryland 21244-1850.

Form CMS-R-131 (Exp. 01/31/2026)

Form Approved OMB No. 0938-0566